Xlife Sciences AG Publishes 2023 Annual Report

Xlife Sciences AG / Key word(s): Annual Results Xlife Sciences AG Publishes 2023 Annual Report 23-Apr-2024 / 07:00 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer is solely responsible for the content of this announcement. Zurich, 23rd of April 2024: Xlife Sciences AG (SIX: XLS) reports on the financial and operational results of 2023 and provides insights into plans for 2024. Despite global uncertainties, the company remains resilient thanks to innovative projects and strategic partnerships, managing to complete its first cash-effective exits.

Operational Progress in 2023

As of December 31, 2023, Xlife Sciences managed 25 project companies, which have made the following notable progress during the reporting year:

• Through the acquisition of Synimmune GmbH at the end of December 2023 via a share deal totaling EUR 32 million, VERAXA Biotech AG successfully expanded its internal cancer portfolio to include innovative antibodies and antibody-drug conjugates with a clinical asset.


• FUSE-AI GmbH received EU MDR Class IIa approval for its AI algorithm «Prostate.Carcinoma.ai». This development opens up commercial potential in 31 countries.


• Successful exits from other portfolio companies: x-diagnostics GmbH, which was acquired by 4D Lifetec AG. This transaction supports the 4D Lifetest in early cancer detection through the AI solution from x diagnostics GmbH. Additionally, cash-effective proceeds of CHF 13.6 million were generated in secondary market transactions.


• Exclusive collaboration between our portfolio company x-kidney diagnostics GmbH and Quant Biomarkers AG, which will advance the asset consisting of innovative biomarkers and lead to a licensing agreement.


• saniva diagnostics GmbH received FDA approval in February 2023 for NeuroMex, a screening device for the early detection of diseases such as Parkinson's and Alzheimer's.


• The strengthening and expansion of the patent families of the individual project companies are key elements for the value of our portfolio. For example, Axenoll Life Sciences AG obtained a strategically significant patent from the European Patent Office at the beginning of 2023.

Financial Highlights 2023